Bone Biologics Corporation
Symbol: BBLG
NASDAQ
1.8001
USDTrhová cena dnes
-0.1011
Pomer P/E
0.0004
Pomer PEG
1.58M
MRK Cap
- 0.00%
Výnos DIV
Bone Biologics Corporation (BBLG) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | -0.3 | -0.6 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.7 | 1 | 0 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.4 | 0 | 0.1 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | -0.8 | 0 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 0.5 | 2.5 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 0.8 | 2.5 | 0.1 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -80.9 | -72 | -70.5 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 83.8 | 77.9 | 77 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -3 | -7.5 | -6.7 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.3 | 0.2 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.1 | -0.2 | -0.3 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.8 | -0.4 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -1 | 0 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -2.2 | 0.5 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 5 | 4.4 | 6.9 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 1.1 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5 | 4.4 | 7.9 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -4.5 | 0.9 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 7.5 | 6.7 | 0 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -9.6 | -3.6 | -1.2 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -9.6 | -3.6 | -1.2 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 9.4 | -0.7 | 0 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | -9.4 | -3.7 | -1.1 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.2 | 0 | ||||||||||||||||
income-statement-row.row.net-income | 0 | -8.9 | 0.7 | -1.6 |
Často kladené otázky
Čo je Bone Biologics Corporation (BBLG) celkové aktíva?
Bone Biologics Corporation (BBLG) celkové aktíva sú 3737763.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.000.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -17.887.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.000.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.000.
Aká je Bone Biologics Corporation (BBLG) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -8948731.000.
Aký je celkový dlh firmy?
Celkový dlh je 0.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 9428303.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 0.000.